AI Penny Stocks: Predictive Oncology (POAI)

Predictive Oncology “is a data and AI-driven discovery services company that provides predictive models of tumor drug response.”
One of Predictive Oncology’s subsidiaries, TumorGenesis, utilizes specific, highly differentiated media in which it grows ovarian cancer cells, and a database of 98 different types of ovarian cancer cells. With these tools, it identifies specific types of tumors and uses that information to create treatments tailored to each patient.

Currently focusing on ovarian cancer, TumorGenesis last year sold “its unique ovarian cancer cell culture media … to a top rated medical university in the New England area for research in isolating and growing ovarian cancer cells.”

Just last month, TumorGenesis announced an alliance with Swedish company Cellevate AB. TumorGenesis indicated that the partners would work to help identify promising targets within tumors, thereby making the development of cancer drugs cheaper and more efficient.
Another Predictive Oncology subsidiary, Helomics, uses AI and its extensive tumor database to test potential cancer drugs “much earlier in the drug discovery process” than usual.

Furthermore, in 2020, Predictive Oncology had revenues of $1.25 million and a gross profit of $805,000. Its market capitalization is $70 million.